COLLAGEN MEDICAL, LLC

Basic Information

23 OAK ST
BELMONT, MA, 02478-3006

http://www.cmed.cc

Company Profile

n/a

Additional Details

Field Value
DUNS: 967097218
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 2


  1. IGF OT IGF SBIR TOPIC TO SUPPORT THE DEVELOPMENT OF TARGET SPECIFIC MOLECULAR IMAGING AGENTS IN COMBINATION WITH EXISTING IMAGING MODALITIES TO DETECT HIGH RISK ATHEROSCLEROTIC PLAQUE

    Amount: $1,499,276.00

    Not Available

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. IGF OT IGF MR CONTRAST AGENT TO QUANTIFY MYOCARDIAL FIBROSIS SBIR TOPIC PHASE II

    Amount: $1,040,592.00

    Not Available

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  3. Fibrin Targeted Cancer Therapy

    Amount: $242,178.00

    DESCRIPTION provided by applicant We propose to improve efficacy of liposomal drugs by active targeting to tumoral fibrin deposits so as to significantly increase biodistribution of drugto the tumo ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  4. Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer

    Amount: $280,588.00

    DESCRIPTION provided by applicant We propose to establish a new method for non invasive characterization of the pancreatic ductal adenocarcinoma PDAC microenvironment by using the collagen specif ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  5. CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging

    Amount: $427,371.00

    DESCRIPTION provided by applicant Assessment of myocardial perfusion is a gatekeeper diagnostic exam that has high sensitivity for identifying individuals with ischemic heart disease Millions of p ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  6. IGF::OT::IGF SBIR Topic 85 To support the development of target specific molecular imaging agents in combination with existing imaging modalities to detect high risk atherosclerotic plaque.

    Amount: $213,776.00

    Not Available

    SBIR Phase I 2014 Department of Health and Human Services
  7. CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging

    Amount: $207,280.00

    DESCRIPTION (provided by applicant): Assessment of myocardial perfusion is a gatekeeper diagnostic exam that has high sensitivity for identifying individuals with ischemic heart disease. Millions of p ...

    SBIR Phase I 2013 Department of Health and Human Services
  8. Optimization of Efficacy and Safety Pharamacology of Fibrosis Imaging Agent CM-65

    Amount: $1,220,519.00

    DESCRIPTION (provided by applicant): Dramatic increases in the incidence of obesity, diabetes, and the metabolic syndrome are increasing the prevalence of chronic liver diseases. Liver fibrosis arisin ...

    SBIR Phase II 2013 Department of Health and Human Services
  9. IGF::OT::IGF MR Contrast Agent to Quantify Myocardial Fibrosis- SBIR Topic 072-

    Amount: $207,554.00

    Myocardial fibrosis is a crucial marker of adverse cardiac remodeling. Research suggests a strong correlationbetween the extent of myocardial fibrosis and adverse myocardial remodeling that occurs aft ...

    SBIR Phase I 2013 Department of Health and Human Services
  10. Optimization of Efficacy and Safety Pharamacology of Fibrosis Imaging Agent CM-65

    Amount: $189,822.00

    DESCRIPTION (provided by applicant): Dramatic increases in the incidence of obesity, diabetes, and the metabolic syndrome are increasing the prevalence of chronic liver diseases. Liver fibrosis arisin ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government